Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y458
UPID:
TBX22_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y458; Q5JZ06; Q96LC0; Q9HBF1
Background:
T-box transcription factor TBX22 plays a pivotal role in developmental processes, particularly in palatogenesis. This protein is a probable transcriptional regulator, orchestrating the complex genetic expressions necessary for the formation of the palate during embryonic development.
Therapeutic significance:
Mutations in TBX22 are linked to Cleft palate with or without ankyloglossia, X-linked, and Abruzzo-Erickson syndrome, highlighting its critical role in craniofacial development. Understanding the role of T-box transcription factor TBX22 could open doors to potential therapeutic strategies for these congenital abnormalities.